(Updated - March 14, 2024 4:33 AM EDT)

RBC Capital analyst Gregory Renza downgraded Spruce Biosciences, Inc. (NASDAQ: SPRB) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Downgrades

Spruce Biosciences, Inc. (SPRB) PT Lowered to $4 at OppenheimerMarch 14, 2024 9:11 AM Spruce Biosciences, Inc. (SPRB) PT Lowered to $3 at JMP Securities, 'We wanted to see a clean safety profile'March 14, 2024 2:40 AM After-hours movers: UiPath, SentinelOne, Under Armour, and moreMarch 13, 2024 4:42 PM Form 8-K SPRUCE BIOSCIENCES, INC. For: Mar 10March 13, 2024 4:13 PM Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate UpdatesMarch 13, 2024 4:08 PM Spruce Biosciences (SPRB) Halted, News PendingMarch 13, 2024 4:02 PM Spruce Biosciences (SPRB) Announces Topline Results from CAHmelia-203March 13, 2024 4:01 PM Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAHMarch 13, 2024 4:01 PM